URGENT FDA Drug Safety Communication: Updated drug labels for Actos

The U.S. Food and Drug Administration (FDA) is informing the public that the Agency has approved updated drug labels for the pioglitazone-containing medicines, including Actos, to include safety information that the use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. FDA previously communicated these labeling changes to the public on June 15, 2011 (Drug Safety Communication). 

The updated drug labels recommend that healthcare professionals should: 

• Not use pioglitazone in patients with active bladder cancer. 
• Use pioglitazone with caution in patients with a prior history of bladder cancer.

 The updated drug labels recommend that patients should: 

• Contact their healthcare professional if they experience any sign of blood in the urine or a red color in the urine or other symptoms such as new or worsening urinary urgency or pain on urination since starting pioglitazone, as these may be due to bladder cancer.

THE LEVENSTEN LAW FIRM REPRESENTS ACTOS USERS FROM AROUND THE COUNTRY. IF YOU OR A LOVED ONE INGESTED ACTOS AND SUFFERS FROM BLADDER CANCER, WE WELCOME YOU TO CONTACT THE LEVENSTEN LAW FIRM TO LEARN HOW TO PROTECT YOUR RIGHTS. YOUR CLAIM IS TIME SENSITIVE. WE URGE YOU TO ACT QUICKLY TO PRESERVE YOUR RIGHT TO BE COMPENSATED FOR YOUR INJURIES CAUSED BY ACTOS.